- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 141039, 5 pages
Genetically Modified Mouse Models Used for Studying the Role of the AT2 Receptor in Cardiac Hypertrophy and Heart Failure
1Department of Internal Medicine, Carney Hospital, Tufts University School of Medicine, Boston, MA 02124, USA
2Department of Cardiovascular Research, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA
Received 18 September 2010; Revised 15 February 2011; Accepted 21 February 2011
Academic Editor: Oreste Gualillo
Copyright © 2011 Maria D. Avila et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. H. Lorell, “Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease,” American Journal of Cardiology, vol. 83, no. 12A, pp. 48H–52H, 1999.
- H. Matsubara, “Renin-angiotensin system in human failing hearts: message from nonmyocyte cells to myocytes,” Circulation Research, vol. 88, no. 9, pp. 861–863, 2001.
- E. F. Grady, L. A. Sechi, C. A. Griffin, M. Schambelan, and J. E. Kalinyak, “Expression of AT2 receptors in the developing rat fetus,” Journal of Clinical Investigation, vol. 88, no. 3, pp. 921–933, 1991.
- Z. Q. Wang, A. F. Moore, R. Ozono, H. M. Siragy, and R. M. Carey, “Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart,” Hypertension, vol. 32, no. 1, pp. 78–83, 1998.
- G. W. Booz and K. M. Baker, “Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy,” Hypertension, vol. 28, no. 4, pp. 635–640, 1996.
- M. D. Schneider and B. H. Lorell, “AT2, judgment day: which angiotensin receptor is the culprit in cardiac hypertrophy?” Circulation, vol. 104, no. 3, pp. 247–248, 2001.
- G. W. Booz, “Cardiac angiotensin AT2 receptor. What exactly does it do?” Hypertension, vol. 43, no. 6, pp. 1162–1163, 2004.
- M. Horiuchi, M. Akishita, and V. J. Dzau, “Recent progress in angiotensin II type 2 receptor research in the cardiovascular system,” Hypertension, vol. 33, no. 2, pp. 613–621, 1999.
- L. H. Opie and M. N. Sack, “Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes,” Circulation Research, vol. 88, no. 7, pp. 654–658, 2001.
- K. Asano, D. L. Dutcher, J. D. Port et al., “Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium,” Circulation, vol. 95, no. 5, pp. 1193–1200, 1997.
- V. Regitz-Zagrosek, N. Friedel, A. Heymann et al., “Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts,” Circulation, vol. 91, no. 5, pp. 1461–1471, 1995.
- T. Senbonmatsu, T. Saito, E. J. Landon et al., “A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy,” The EMBO Journal, vol. 22, no. 24, pp. 6471–6482, 2003.
- S. Izumo and T. Shioi, “Cardiac transgenic and gene-targeted mice as models of cardiac hypertrophy and failure: a problem of (new) riches,” Journal of Cardiac Failure, vol. 4, no. 4, pp. 263–270, 1998.
- X. Yan, R. L. Price, M. Nakayama et al., “Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice,” American Journal of Physiology, vol. 285, no. 5, pp. H2179–H2187, 2003.
- H. Masaki, T. Kurihara, A. Yamaki et al., “Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects,” Journal of Clinical Investigation, vol. 101, no. 3, pp. 527–535, 1998.
- T. Ichiki, P. A. Labosky, C. Shiota et al., “Effects on blood pressure exploratory behaviour of mice lacking angiotensin II type 2 receptor,” Nature, vol. 377, no. 6551, pp. 748–750, 1995.
- L. Hein, G. S. Barsh, R. E. Pratt, V. J. Dzau, and B. K. Kobilka, “Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice,” Nature, vol. 377, no. 6551, pp. 744–747, 1995.
- Z. Yang, C. M. Bove, B. A. French et al., “Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction,” Circulation, vol. 106, no. 1, pp. 106–111, 2002.
- H. Sugino, R. Ozono, S. Kurisu et al., “Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice,” Hypertension, vol. 37, no. 6, pp. 1394–1398, 2001.
- M. Nakayama, X. Yan, R. L. Price et al., “Chronic ventricular myocyte-specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction,” American Journal of Physiology, vol. 288, no. 1, pp. H317–H327, 2005.
- X. Yan, A. J. T. Schuldt, R. L. Price et al., “Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes,” American Journal of Physiology, vol. 294, no. 3, pp. H1274–H1281, 2008.
- T. Senbonmatsu, S. Ichihara, E. Price, F. A. Gaffney, and T. Inagami, “Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload,” Journal of Clinical Investigation, vol. 106, no. 3, pp. R25–R29, 2000.
- S. Ichihara, T. Senbonmatsu, E. Price, T. Ichiki, F. A. Gaffney, and T. Inagami, “Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension,” Circulation, vol. 104, no. 3, pp. 346–351, 2001.
- M. Akishita, M. Iwai, L. Wu et al., “Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice,” Circulation, vol. 102, no. 14, pp. 1684–1689, 2000.
- Y. Adachi, Y. Saito, I. Kishimoto et al., “Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice,” Circulation, vol. 107, no. 19, pp. 2406–2408, 2003.
- Y. Tsutsumi, H. Matsubara, N. Ohkubo et al., “Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression,” Circulation Research, vol. 83, no. 10, pp. 1035–1046, 1998.
- M. Stoll, U. M. Steckelings, M. Paul, S. P. Bottari, R. Metzger, and T. Unger, “The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells,” Journal of Clinical Investigation, vol. 95, no. 2, pp. 651–657, 1995.
- C. A. M. Van Kesteren, H. A. A. Van Heugten, J. M. J. Lamers, P. R. Saxena, M. A. D. H. Schalekamp, and A. H. J. Danser, “Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts,” Journal of Molecular and Cellular Cardiology, vol. 29, no. 8, pp. 2147–2157, 1997.
- M. Nakajima, H. G. Hutchinson, M. Fujinaga et al., “The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 23, pp. 10663–10667, 1995.
- A. D'Amore, M. J. Black, and W. G. Thomas, “The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy,” Hypertension, vol. 46, no. 6, pp. 1347–1354, 2005.
- R. E. Widdop, E. S. Jones, R. E. Hannan, and T. A. Gaspari, “Angiotensin AT2 receptors: cardiovascular hope or hype?” British Journal of Pharmacology, vol. 140, no. 5, pp. 809–824, 2003.
- N. Ohkubo, H. Matsubara, Y. Nozawa et al., “Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism,” Circulation, vol. 96, no. 11, pp. 3954–3962, 1997.
- J. Wharton, K. Morgan, R. A. D. Rutherford et al., “Differential distribution of angiotensin AT2 receptors in the normal and failing human heart,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 1, pp. 323–336, 1998.